

## Interim report January – September 2024

### Important events during the quarter


- Enrollment completion of patients to additional 450 µg/kg cohort in mitazalimab Phase 2 trial OPTIMIZE-1
- Presentation of positive interim Phase 1 data for drug candidate ALG.APV-527 at ESMO congress

“Mitazalimab’s Phase 3 initiation is on track for 2025, where the strong data so far suggests promising long-term survival benefits for pancreatic cancer patients.”

### Financial information

| MSEK, unless otherwise stated                     | 2024<br>Jul-Sep | 2023<br>Jul-Sep | 2024<br>Jan-Sep | 2023<br>Jan-Sep |
|---|-----------------|-----------------|-----------------|-----------------|
| Net sales   | 1.4             | 19.4            | 16.0            | 46.4            |
| Operating profit/loss                             | -62.0           | -52.7           | -169.1          | -178.6          |
| Profit/loss for the period                        | -66.5           | -52.5           | -178.5          | -178.8          |
| Cash flow for the period                          | -29.5           | -86.5           | -18.3           | -23.1           |
| Cash and cash equivalents                         | 47.8            | 123.9           | 47.8            | 123.9           |
| Earnings per share before and after dilution, SEK | -0.09           | -0.08           | -0.25           | -0.45           |

### PIPELINE PROJECTS



# CEO comments

As we progress with preparations for our lead asset's Phase 3 evaluation, we have diligently continued our efforts over the last few months to identify the best global partner for mitazalimab. This partnership aims to advance our candidate through the next stage of its clinical and regulatory development, to ensure both significant benefits for patients with hard-to-treat cancers and commercial success. Looking at our next major milestone, we remain on track for Phase 3 initiation under the first half of 2025.

## Mitazalimab on track for Phase 3 initiation

Following the outstanding performance of mitazalimab in both the OPTIMIZE-1 Phase 2 top-line results and the 18-month follow-up data, we have been progressing our preparations for its advancement into Phase 3. We have completed enrollment of patients in the 450 µg/kg back-fill cohort of the OPTIMIZE-1 trial. This additional cohort will provide further dose characterization following advice from the US Food and Drug Administration (FDA) to ensure mitazalimab's readiness for Phase 3 initiation. We have also finalized the development of our commercial manufacturing processes, and initiated manufacturing to support the Phase 3 study, an important milestone in Phase 3 preparations. In parallel, we are continuing our discussions with regulators in the US and Europe ahead of the commencement of a Phase 3 trial in the first half of next year.

Mitazalimab's clinical performance so far has clearly demonstrated its ability to offer highly promising long-term survival benefits to those suffering from pancreatic cancer when combined with chemotherapy. This is reflected by the fact that more than a quarter of the patients are still in the study, 19 months after completion of recruitment. We look forward to providing 24 months follow-up data during Q1 2025; a milestone that sets mitazalimab apart from other treatments in metastatic pancreatic cancer.

“Mitazalimab's Phase 3 initiation is on track for 2025, where the strong data so far suggests promising long-term survival benefits for pancreatic cancer patients.”

While our goal remains to secure a commercial partner for mitazalimab at beneficial terms for our shareholders, we are also working on expediting mitazalimab through the last stages of its clinical development to make it available to patients as fast as possible.

## Positive ALG.APV-527 data presented at the ESMO Congress

This quarter, we presented positive interim Phase 1 data from ALG.APV-527 in a poster session at the European Society for Medical Oncology (ESMO) Annual Congress, in Barcelona. This first-in-class antibody, co-developed with Aptevo Therapeutics, is being evaluated as a monotherapy in multiple solid tumor types and has demonstrated a good safety and tolerability profile along with signs of biological activity. Top-line data from the Phase 1 study are due in Q1 2025 and we are looking forward to the insights they should offer about how ALG.APV-527 can be progressed into later stage development.

## Upcoming Warrants Series subscription period

Looking ahead to the next quarter, Warrants Series TO 9 holders will be able to utilize their warrants from December 4 at a 10 per cent discount from the November volume weighted share price, which we expect will improve our liquidity position.



I would like to thank all our stakeholders, in particular our investors for their unwavering support and our employees for their diligence and commitment to our goal. I look forward to updating you again in a few months from now, as we close out the year in what will be a productive final quarter of 2024.

**Søren Bregenholt**

CEO Alligator Bioscience AB (publ)

# Performance measures


## Group

|   | Note | 2024<br>Jul-Sep | 2023<br>Jul-Sep | 2024<br>Jan-Sep | 2023<br>Jan-Sep | 2023<br>Jan-Dec |
|---|------|-----------------|-----------------|-----------------|-----------------|-----------------|
| <b>Result (KSEK)</b>                                |      |                 |                 |                 |                 |                 |
| Net sales   | 5    | 1,433           | 19,414          | 15,988          | 46,369          | 58,107          |
| Operating profit/loss                               |      | -62,038         | -52,720         | -169,052        | -178,596        | -248,983        |
| Profit/loss for the period                          |      | -66,511         | -52,501         | -178,475        | -178,756        | -248,586        |
| R&D costs   |      | -52,671         | -62,952         | -151,027        | -193,477        | -264,585        |
| R&D costs as a percentage of operating costs, %     |      | 82%             | 87%             | 81%             | 85%             | 85%             |
| <b>Capital (KSEK)</b>                               |      |                 |                 |                 |                 |                 |
| Cash and cash equivalents at end of period          |      | 47,797          | 73,919          | 47,797          | 73,919          | 66,118          |
| Cash, cash equivalents and bonds at end of period   |      | 47,797          | 123,919         | 47,797          | 123,919         | 66,118          |
| Cash flow from operating activities                 |      | -57,710         | -46,567         | -178,694        | -134,785        | -189,286        |
| Cash flow for the period                            |      | -29,543         | -86,495         | -18,270         | -23,098         | -30,184         |
| Equity at the end of the period                     |      | -76,004         | 81,897          | -76,004         | 81,897          | 11,855          |
| Equity ratio at the end of the period, %            |      | -83%            | 44%             | -83%            | 44%             | 10%             |
| <b>Info per share</b>                               |      |                 |                 |                 |                 |                 |
| Average number of shares                            |      | 758,039,236     | 632,567,111     | 725,481,482     | 399,466,214     | 448,489,815     |
| Earnings per share before and after dilution* (SEK) |      | -0.09           | -0.08           | -0.25           | -0.45           | -0.55           |
| Equity per share before potential dilution (SEK)    |      | -0.10           | 0.12            | -0.10           | 0.12            | 0.02            |
| <b>Personnel</b>                                    |      |                 |                 |                 |                 |                 |
| Number of employees at end of period                |      | 47              | 59              | 47              | 59              | 58              |
| Average number of employees                         |      | 49              | 60              | 53              | 56              | 56              |
| Average number of employees employed within R&D     |      | 39              | 52              | 43              | 48              | 46              |


\* Effect from dilution is not considered when result is negative and options where call rate is higher than closing rate is not considered.

For definitions and calculations, see the sections later in this report.

### Operating costs distributed by function, Parent Company



### Operating costs, rolling 12 months and Liquidity (MSEK), Group





# Market overview

Cancer's impact is widespread, affecting patients and their loved ones. As cancer diagnoses continue to rise globally, the demand for more effective treatments is increasing. Alligator is developing drug candidates that strike the right balance between effectiveness and tolerability. These drugs can be used alongside standard cancer treatments to address hard-to-treat cancers, potentially offering a cure.

Alligator is positioned as a leader in the immuno-oncology industry, either developing first-in-class or best-in-class antibodies targeting highly relevant immune activation pathways. We are convinced of the safety and efficacy benefits of combination treatments and our antibodies are designed with features that make them complementary to existing cancer therapies. This gives our antibodies a unique position of potentially being a part of tomorrow's combination therapies for the treatment of cancer.

## The Oncology Market

The high societal costs of cancer care are a direct result of a rise in cancer cases, coupled to an increased longevity, which increases the likelihood of developing cancer. Improved awareness, screening, and diagnostic accuracy also results in more cancers being detected, more often, and at an earlier stage, which improves the probability of treatment success.

In 2022, sales of oncology drugs amounted to USD 265 billion, an increase of more than USD 100 billion from 5 years earlier.<sup>1</sup> The oncology drug market is expected to more than double by 2028 to USD 542 billion, accounting for approximately 40% of the total drug market.<sup>1</sup> A surge of new and innovative treatment methods is expected to emerge in the marketplace, and Alligator believes that immunotherapies will play a central role in these treatment options for cancer.

## The Immuno-Oncology Market

Immuno-oncology is a form of cancer therapy that aims to stimulate the immune system to attack tumors. 64 of the antibody-based drugs approved in Europe and/or the United States are in oncology, including several major immuno-oncology brands such as Keytruda® (Merck), Opdivo® (BMS), Tecentriq® (Roche) and Yervoy® (BMS).<sup>1</sup>

There have been major advances in immuno-oncology in recent years and the immunotherapy drug market is expected to grow rapidly in the years ahead.<sup>1</sup> The average cost of treatment with existing immunotherapies is high. For example, the list price of Keytruda® is about USD 15,000 per patient, per month in the US.<sup>2</sup> Although the cost of immunotherapies is high, the loss of patent exclusivity of earlier generation drugs helps keep costs under control and allows more patients to be treated with the latest generation of products.

## The Pancreatic Cancer Market

Pancreatic cancer is one of the most challenging cancers to treat and has one of the lowest five-year survival rates of any cancer. Approximately 300,000 people in the 16 major markets\* are diagnosed with pancreatic cancer each year.<sup>1</sup> Although surgery is the best treatment, only 15-20% of those diagnosed can be treated by surgery, while the remaining 85% are left with very few treatment options available to them, with chemotherapy regimens being the standard of care.<sup>1</sup>

\*) 16 main markets include: Australia, Brazil, Canada, France, Germany, India, Italy, Japan, Mexico, Russia, South Africa, South Korea, Spain, UK, US, Urban China



Today's pancreatic cancer market, dominated by chemotherapies, is approximately USD 2 billion, and is expected to increase to approximately USD 5.4 billion by 2029.<sup>1</sup> The pancreatic cancer market is expected to increase significantly with the approval of novel innovative immunotherapies such as mitazalimab.

## Cancer Treatment Market Trends

Alligator believes that the need and demand for novel immunotherapy drugs will increase along with the global demand for new and more effective oncology therapies. The main market trends identified by the company include:

- A global rise in annual cancer diagnosis
- A growing number of applications for immunotherapy
- An increased need for safe and effective combination therapies
- An improved access to innovative medicines
- An increased expenditure and investment in immunotherapy drug development

## References

1. Database GlobalData (Pharma Intelligence Center - Drug Sales), February 2023.
2. [www.keytruda.com/financial-support/](http://www.keytruda.com/financial-support/), February 2023

# Operations

Our technology platforms and pharmaceutical research cultivate long-term value and attract interest from potential partners, and we ensure competitive, efficient development of our programs through collaborations with leading biotech firms, labs and research institutions. Our oncology expertise is further enhanced by conducting clinical trials alongside specialist physicians and CROs.

Alligator has had a strong start to 2024, reporting promising top line data for lead candidate mitazalimab in the trial OPTIMIZE-1—a Phase 2 study that underscores the Company's in-house expertise and strategic partnerships in navigating projects from conception to clinical development.

## Alligator's organization

Alligator's research and development organization is divided into five units: Discovery, Chemistry, Manufacturing & Control (CMC), Non-Clinical Development, Medical Science and Clinical Operations. Members of all these functions collaborate cross-functionally in project teams. The **Discovery** unit is responsible for early-stage research projects up until a drug candidate has been identified. This normally includes the development and evaluation of treatment concepts, the evaluation of potential drug candidates


and early-stage confirmation of efficacy. The **CMC** unit develops manufacturing processes and is responsible for clinical trial material manufacturing. The **Non-Clinical Development** unit is responsible for pre-clinical evaluation of safety and efficacy of our molecules, including preparation of the data packages required for clinical trial applications. The **Medical Science** unit is responsible for designing all the clinical and regulatory development plans required to show that Alligator's products are safe and effective. The **Clinical Operations** unit is responsible for timely and excellent implementation of the clinical trials. Alligator continues to build and shape the organization to match and support its strategy and objectives.

## Several proprietary technologies

Alligator's proprietary technologies and antibody libraries enable efficient generation of novel drug candidates with high therapeutic potential. A great recent addition to our technologies is RUBY®, an antibody format that allows Alligator to generate dual-action bispecific antibodies, with excellent properties in terms of stability and manufacturing yield. This eliminates the need for further optimization and enables rapid advancement to clinical development.

With our 3rd generation technology platform, Neo-X-Prime®, we aim at a more personalized immunotherapy, with bispecific antibodies binding to tumor and tumor particles and to dendritic cells through the CD40 molecule. The resulting interaction between the two targets leads to an efficient education and activation of tumor-specific T cells, that subsequently recognize and destroy the tumor cells.

## Design of highly efficient antibodies through Alligator's proprietary technologies



## Business model that creates value across the development chain

Alligator combines internal expertise in proprietary drug development with strategic partnerships, optimizing our portfolio's value by advancing lead molecules from preclinical studies through Phase 2 clinical trials and beyond.

Our technologies and partnerships enable us to create candidates with inherent value across the development chain, enabling income generation, risk mitigation and an enhanced long-term value.

# How Alligator promotes sustainability


We believe our commitment to sustainability, transparency and diversity drives our immuno-oncology innovation. From sustainable operations to fostering an inclusive culture, we are working towards our common goal of delivering best-in-class treatments for patients with hard-to-treat cancers.

## Sustainable operations meeting high standards

Alligator is deeply committed to corporate responsibility and sustainability, integrating these principles into our daily operations. We strive to exceed established requirements in ecological, social, and economic sustainability. Our efforts include monitoring and reducing our environmental footprint, updating travel policies for reduced CO<sub>2</sub> emissions, and integrating ESG and DEI objectives into our corporate goals.

## Contributing to global sustainable development

Aligned with the United Nations' Sustainable Development Goals, we actively contribute to goals 3, 5 and 8, focused on good health and well-being, gender equality, and decent work and economic growth. As a company developing immuno-oncology drugs, we prioritize patient health, foster an inclusive and diverse workplace, and uphold fair working conditions essential for innovation and growth.



## Transparency and engagement with stakeholders

Alligator values transparency and actively engages with stakeholders. Through our website, social media channels, and press releases, we provide up-to-date information tailored to various levels of expertise. Our commitment to corporate responsibility is evident through our Nasdaq ESG Transparency Partner certification and our dedication to providing clear governance.

## Fostering a supportive work environment

At Alligator, we cultivate an environment where dedicated employees thrive. Our clinical-stage biotechnology company attracts leading expertise by offering growth opportunities, academic recognition, and a supportive team spirit. With a focus on diversity and inclusion, we aim to create equal opportunities for all employees, as reflected in our rankings on equality reports and diversity indices.

## Core values and internal career development

Our organizational culture is guided by four core values: collaboration, curiosity, trust, and accountability. These values shape how we operate and interact to achieve our vision. We prioritize internal career development, offering opportunities for employees to grow within the company. Our commitment to diversity, equity, and inclusion is embedded in our DEI policy, fostering innovation in a psychologically safe environment.

By maintaining high standards of sustainability, engaging with stakeholders transparently, fostering a supportive work



environment, and prioritizing diversity and inclusion, Alligator continues to drive innovation and success in immuno-oncology.

# Alligator's project portfolio

Alligator's competitive project portfolio consists of the two clinical-stage assets, mitazalimab and ATOR-1017, and ATOR-4066, a pre-clinical program developed using Alligator's proprietary technology platform Neo-X-Prime® – as well as several programs developed in collaboration with partners.

## Mitazalimab

Mitazalimab was developed using Alligator's proprietary technology platforms. In preclinical experimental models, mitazalimab has been shown to induce a potent tumor-targeted immune response, and to provide long-lasting tumor immunity against multiple types of cancer. The preclinical experiments also demonstrated that mitazalimab acts synergistically with other cancer therapies such as chemotherapy, checkpoint inhibitors, and cancer vaccines. Preclinical data also demonstrated that mitazalimab is effective in chemotherapy-resistant cancer cells.

A Phase 1 study with mitazalimab conducted by Janssen Biotech Inc., including 95 patients, showed signs of efficacy, proof-of-mechanism, as well as a manageable safety profile.

### OPTIMIZE-1 – A highly promising Phase 2 trial

In the third quarter of 2021, the first patient was dosed in OPTIMIZE-1, a Phase 2 study designed to further assess the efficacy and safety of mitazalimab in combination with standard-of-care chemotherapy, mFOLFIRINOX, for the treatment of first-line metastatic pancreatic cancer. The single arm, open-label, multi-center study is performed at clinical sites in Belgium, France and Spain, and has evaluated the efficacy of mitazalimab at the 900 µg/kg dose in 57 patients in total. The chemotherapy cocktail used, mFOLFIRINOX, kills tumor cells leading to increased release of tumor antigens. This, together with the activation of CD40 by mitazalimab leads to improved presentation of tumor antigens, and the consequent induction of T cell-dependent antitumor responses.

### Project status: Completion of enrollment for additional cohort in OPTIMIZE-1


In July, Alligator announced the completion of enrollment for the additional cohort with 450 µg/kg of mitazalimab in combination with mFOLFIRINOX. This was a request from US FDA prior to entering Phase 3, and marks an important step in preparing for the candidate's continued clinical development.

Top-line results from OPTIMIZE-1 were announced in January 2024, nine months earlier than originally planned, which were followed by an 18-months survival follow-up in June, demonstrating an increase in ORR to 42.1% (40.4%) and in median Overall Survival (mOS) to 14.9 months (14.3 months) in the entire patient population. The Duration of Response was an unprecedented 12.6 months. These strong data are noteworthy, especially in the light of an ORR of 31.6% reported with FOLFIRINOX in a similar patient population and the 11.1 months of mOS demonstrated by FOLFIRINOX over a decade ago<sup>1</sup> and confirmed by the 11.1 months demonstrated by NALIRIFOX in 2023<sup>2</sup>.

### External interest

During 2024, mitazalimab data has been presented at leading medical conferences such as the AACR and ASCO Annual Meetings, as well as at ESMO GI.

In June 2024, results from the OPTIMIZE-1 trial were published in the renowned scientific journal *The Lancet Oncology*. Alligator views this as a testament to the great interest in mitazalimab's potential in pancreatic cancer.



Alligator receives much interest from the scientific community and continuously engages in discussions with investigators expressing interest in mitazalimab, and other assets. This strategic approach is in line with our commitment to fostering collaborations and transparent communication within the industry and academia. In May 2024, the Company announced an Investigator-Initiated Trial with mitazalimab, conducted by Moore's Cancer Center at UC San Diego.

### Regulatory and Intellectual Property Achievements


During 2023, Alligator received Orphan Drug Designation for mitazalimab in pancreatic cancer from the US Food and Drug Administration (FDA) and Orphan Designation from the European Medicines Agency (EMA). These orphan designations confer significant regulatory and financial benefits, including marketing exclusivity upon approval, giving mitazalimab stronger commercial protection in the two key markets of the US and EU.

Alligator also strengthened the mitazalimab Intellectual Property position in 2023 with a new patent granted by the European Patent Office covering mitazalimab's composition of matter until 2038. This new patent provides vital further protection for Alligator's lead asset in Europe and is a significant addition to the mitazalimab patent portfolio, which now stands at 48 granted patents and 25 pending patents covering multiple territories, including Europe, North America, Asia and more. Protecting its intellectual property is a key pillar of Alligator's business strategy and provides a strong foundation for its drug development program and partnering discussions.

In April 2023, the FDA cleared Alligator's Investigational New Drug (IND) application for the OPTIMIZE-2 Phase 2 trial to evaluate mitazalimab in urothelial carcinoma, which will hedge the medical risk and maximize the long-term value of mitazalimab.



# ATOR-4066



## Innovative integration for enhanced therapeutic potential

ATOR-4066 is a bispecific antibody developed using our technology platform Neo-X-Prime®. This platform integrates Alligator's expertise in immuno-oncology and CD40-targeted therapies with our bispecific antibody format, RUBY®. The approach involves antibodies binding to both CD40 and molecules preferentially expressed on tumor cells, which not only activates dendritic cells directed at tumors but also links circulating tumor material to dendritic cells. This linkage educates and activates tumor neoantigen-specific T cells, resulting in superior anti-tumor activity. Besides CD40, ATOR-4066 binds CEACAM5, a tumor-associated antigen found predominantly in colorectal, gastric and pancreatic cancers.


## Single-agent complete responses in preclinical tumor models

Preclinical data supporting ATOR-4066's mechanism of action and potent anti-tumor effects, as well as the potential of the Neo-X-Prime® platform, has been presented at various scientific meetings and in scientific articles, recently in April 2024 at the AACR Annual Meeting. These presentations collectively demonstrate ATOR-4066's ability to reshape the immune microenvironment and activate tumor-infiltrating immune cells has shown to lead to single-agent complete responses in translational tumor models. This affirm its potential as a promising drug candidate, supporting further development towards clinical trials.

## Continued advancement and patent milestone

Alligator focuses its efforts on activities to support the preclinical ATOR-4066 data package and preparing for its clinical development. In early 2024, the first US patent for ATOR-4066, providing protection for methods of treating cancer and/or tumors using a bispecific antibody comprising the binding regions of the 4066 molecule.

# ATOR-1017



## Enhancing immune activation with ATOR-1017

ATOR-1017, a 4-1BB agonist with a unique profile, most importantly by enhancing immune activation within tumors, presenting opportunities for potent, tumor-directed immune responses. This capability holds promise for increasing therapeutic efficacy while minimizing adverse effects in patients.


## Clinical advancements and promising results

Findings from Alligator's Phase 1 dose-escalation study, successfully completed in September 2022, demonstrated the safety and tolerability of ATOR-1017 in patients with advanced solid cancers, and established its safety and tolerability at doses up to 900 mg/kg. The results were presented at scientific conferences, positioning it as a potential best-in-class asset. Subsequent data published in the journal *Cancer Immunology, Immunotherapy* in October 2023, revealed the potent activity of ATOR-1017, both *in vitro* and *in vivo*, as monotherapy and in combination with anti-PD-1 treatment. These results, coupled with the Phase 1 study outcomes, support further development of ATOR-1017 in patients with histologically confirmed, advanced, and/or refractory solid cancer.

## Future development and partnership goals

Continued efforts are focused on securing a partnership to capitalize on these promising clinical foundations and advance ATOR-1017 to its next development milestone.

# ALG.APV-527



## A collaboration to pioneer bispecific therapy for solid tumors

ALG.APV-527, a bispecific antibody targeting 4-1BB and 5T4, is specifically designed for the treatment of metastatic solid tumors. In 2017, Aptevo Therapeutics and Alligator signed a co-development agreement, resulting in both companies equally owning and financing the asset's development. The original molecules involved in the tumor-binding function and the immunomodulatory function of the candidate were developed using Alligator's patented ALLIGATOR-GOLD® antibody library. Aptevo's ADAPTIR™ technology platform further improved the bispecific molecule, combining tumor-binding and immunomodulatory functions within the same molecule. This design allows ALG.APV-527 to selectively target tumors and stimulate antitumor-specific immune cells present within the tumor microenvironment.

## Clinical progress and preliminary results

In February 2023, the first patient was dosed in the multi-center, dose-escalation trial for ALG.APV-527, evaluating the candidate in treatment of solid tumors expressing the tumor-associated antigen 5T4. The trial is currently more than 50% enrolled, and initial results reported in February 2024 indicate an overall well-tolerated candidate, with biomarker analyses confirming biological activity.

In September 2024, results from the Phase 1 monotherapy study were presented at the European Society of Medical Oncology conference and demonstrated that 60% of evaluable patients with solid tumors achieved stable disease.

## Recognition in the scientific community

Preclinical data highlighting the potential of ALG.APV-527 has been presented at conferences and published in the scientific journal *Molecular Cancer Therapeutics* in November 2022. The publication showcased favorable preclinical efficacy and safety data of ALG.APV-527 compared to first-generation 4-1BB antibodies.



# Collaborations and Out-Licensing Agreements

## Orion Corporation

### Strategic Partnership for Bispecific Cancer Therapeutics

In 2021, Alligator forged a research collaboration and license agreement with Orion Corporation, a leading global pharmaceutical company headquartered in Finland. The primary objective of this collaboration is to explore novel bispecific antibody cancer therapeutics targeting immuno-oncology targets. The agreement encompasses an option to develop three bispecific antibodies, with a notable milestone achieved in January 2023 when Orion exercised its option to commence a second program within the collaboration, and later in April.

### Key Terms and Milestones

Under this partnership, Alligator leverages its proprietary phage display libraries and RUBY® bispecific platform. Throughout the initial research phase, Alligator is eligible for upfront payments as well as reimbursement for research costs and associated fees. The agreement also outlines potential milestone payments totaling up to EUR 313 million tied to development, regulatory approval, and sales milestones.

Additionally, should Orion proceed with the development and commercialization of resulting product candidates, Alligator stands to receive additional royalty payments. Recent milestones include Orion's selection of bispecific lead antibodies on May 11, 2023, the achievement of Technical Feasibility in the second collaboration project on July 31, 2023, and selection of lead antibodies on April 26, 2024, all events triggering milestone payments to Alligator.

## MacroGenics, Inc.

### Strategic Partnership for Innovative Cancer Therapeutics

In 2021, Alligator entered a joint research collaboration with US-based MacroGenics, Inc., a Nasdaq-listed biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The research collaboration utilizes Alligator's proprietary myeloid engaging Neo-X-Prime® platform to develop bispecific antibodies against two undisclosed targets.

Under the joint research collaboration agreement, which covers activities from candidate drug generation up until IND-enabling studies, each company is responsible for its own costs. The parties may continue further development of the resulting bispecific molecule under a separate co-development collaboration and licensing agreement.

## Biotheus

### Expanding Reach: Alligator's Partnership with Biotheus

In 2019, Alligator finalized an agreement with the Chinese company Biotheus, granting Biotheus the Chinese rights (including Greater China, Hong Kong, Taiwan, and Macao) to an antibody from the ALLIGATOR-GOLD® antibody library. The agreement stipulates that Alligator is entitled to total initial upfront payments, along with milestone and option payments potentially totaling USD 142 million. To date, Alligator has received upfront payments amounting to approximately SEK 10 million.

## AC101/HLX22

### Clinical project developed by Shanghai Henlius


Through its subsidiary Atlas Therapeutics AB, Alligator holds a participating interest in the clinical Biosynergy (AC101/HLX22) project, run by the listed Korean company AbClon. The drug candidate is now being further developed by the Chinese company Shanghai Henlius, which increased its rights to encompass a global license for development and commercialization in 2018. Shanghai Henlius has initiated two clinical trials:

- A Phase 1 single-center, open-label, dose-escalation clinical trial to evaluate the safety and the tolerability of AC101/HLX22 in patients with advanced solid tumors overexpressing HER2 after failure of standard of care. The trial, completed in 2021, enrolled 11 patients, and has not yet published its conclusions.
- A Phase 2 multi-center randomized, double-blinded clinical trial to evaluate the clinical efficacy and safety of AC101/HLX22 as first-line therapy in HER2+ locally advanced or metastatic gastric cancer. The study aims to enroll 150 patients, with an estimated study completion in 2024.

In May, 2024, Henlius Biotech received an FDA-clearance on their IND-application for a Phase 3 trial with HLX22 (AC101) in Gastric Cancer.

### Potential revenue share and milestones in project

Alligator incurs no cost for this project and is entitled to 35% of AbClon's revenue from out-licensing to Shanghai Henlius. In previous financial years, Alligator received two milestone payments totaling USD 3 million in conjunction with regional and global out-licensing.



# The Alligator Share

## Number of shares, stock option program and share saving program

The total number of outstanding shares in the Company is 758,989,086, of which 758,039,236 are ordinary shares with one vote per share and 949,850 are series C shares with one-tenth of a vote per share. The number of votes in the Company amounts to 758,134,221 votes.

The Extraordinary General Meeting on 14 March 2024 resolved to carry out a rights issue and to reduce the share capital within the aggregate SEK 41,642,741.648 from SEK 42,169,864.96 to SEK 527,123.312. This reduction means that the quota value per share was reduced from SEK 0.064 to SEK 0.008. During the Rights Issue in April 2024, 100,084,946 units were subscribed for, comprised of one ordinary share and one warrant, TO 9.

One warrant series TO 9 will entitle the holder to subscribe for one new ordinary share in the Company at an exercise price corresponding to 90 percent of the volume-weighted average price of the Company's share on Nasdaq Stockholm during the period from and including November 4, 2024, up to and including November 29, 2024, however not less than the quota value of the share. The exercise period will run between December 4, 2024, to December 18, 2024.

## The Alligator share in brief September 30, 2024

|                           |   |
|---------------------------|---|
| Listed on:                | Nasdaq Stockholm Small Cap  |
| Number of shares:         | 758,989,086<br>(758,039,236 ordinary shares and 949,850 C shares) |
| Average turnover per day: | Approximately 2,043,374<br>(preceding quarter: approx. 2,271,236) |
| Number of shareholders:   | 11,909 (preceding quarter: approx. 11,576)                        |
| Market capitalization:    | SEK 993 million<br>(preceding quarter: approx. SEK 911 million)   |
| Ticker:                   | ATORX   |
| ISIN:                     | SE0000767188  |

## Swedish and foreign ownership



## Largest Shareholders, September 30, 2024

|   | No of Shares       | %            |
|---|--------------------|--------------|
| Koncentra Holding AB<br>(Part of Allegro Investment Fund) | 249,948,629        | 32.9         |
| Roxette Photo SA  | 64,899,291         | 8.6          |
| Avanza Pension  | 21,010,002         | 2.8          |
| Magnus Petersson  | 21,003,952         | 2.8          |
| Nordnet Pensionsförsäkring                                | 17,841,973         | 2.4          |
| Johan Zetterstedt   | 17,000,000         | 2.2          |
| Handelsbanken Fonder                                      | 13,938,354         | 1.8          |
| Lars Spånberg   | 9,641,572          | 1.3          |
| Jonas Sjögren   | 5,536,486          | 0.7          |
| Zetterstedt Holding AB                                    | 5,223,132          | 0.7          |
| Other shareholders  | 331,995,845        | 43.8         |
| <b>Total number of shares</b>                             | <b>758,039,236</b> | <b>100.0</b> |

The Company's owner structure is updated regularly on the Company's website: [www.alligatorbioscience.com](http://www.alligatorbioscience.com)

Source: Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority (Finansinspektionen).

# The Alligator Share cont.

## Share saving program LTI 2021

At the Annual General Meeting 2021 it was resolved to implement a long-term incentive program by way of a performance-based share saving program for employees in the Group ("LTI 2021"). For each ordinary share acquired by the participant on Nasdaq Stockholm, so called saving shares, the participant has a right to receive so called Matching shares and earning performance shares. Allotment of Matching shares will take place within 60 days after 30 September 2024. The requirement for earning performance shares was however not met.

After the recalculation due to rights issues prior to 2024 the maximum number of ordinary shares that can be issued in relation to LTI 2021 amounts to 214,005 whereby 162,840 for the deliverance of Matching shares to participants and 51,165 to hedge payments of social security contributions. Additional recalculation due to the Rights issue in 2024, will be performed close in time to the allotment of Matching shares.

## Warrant programs, LTI 2022 I/II

At the annual general meeting 2022 it was resolved to implement a long-term incentive program by way of a warrant program for employees in the Group and for certain board members ("LTI 2022-I", respectively "LTI 2022-II"). Each warrant in LTI 2022-I/II entitles to subscription of one ordinary share in the Company. Subscription of shares by virtue of the warrants may be effected as from 1 June 2025 up to and including 30 June 2025. Due to rights issues the subscription price per share for above warrant programs, has been recalculated to SEK 2.57. In case all warrants held by participants are utilized for subscription of new ordinary shares, a total of 3,704,979 new ordinary shares will be issued, which corresponds to a dilution of approximately 0.5 per cent of the Company's ordinary shares after full dilution. The warrants will also be subject to further recalculation based on the right issue in 2024, after the subscription price for TO 9 is determined. All warrants have been transferred to the participants at fair market value.

## Warrant programs 2023/2023-II

At the annual general meeting 2023 it was resolved to implement another long-term incentive program by way of a warrant program for employees in the Group and for certain board members ("Warrant program 2023", respectively "Warrant program 2023-II"). The subscription price for one share is currently SEK 1.06 and the program runs for three years. In case all warrants held by participants are utilized for subscription of new ordinary shares, a total of 7,895,000 new ordinary shares will be issued, which

corresponds to a dilution of approximately 1.0 per cent of the Company's ordinary shares after full dilution. The warrants will be subject to recalculation based on the right issue in 2024, after the subscription price for TO 9 is determined. All warrants have been transferred to the participants at fair market value.

## Warrant programs 2024/2024-II

At the annual general meeting 2024 it was resolved to implement another long-term incentive program by way of a warrant program for employees in the Group and for certain board members ("Warrant program 2024", respectively "Warrant program 2024-II"). The subscription price for one share is SEK 1.69 and the program runs for three years. In case all warrants held by participants are utilized for subscription of new ordinary shares, a total of 3,354,166 new ordinary shares will be issued, which corresponds to a dilution of approximately 0.4 per cent of the Company's ordinary shares after full dilution.

In case both the existing share saving program as well as the warrants held by participants are exercised, a total of 15,168,149 ordinary shares will be issued, which corresponds to a total dilution of approximately 2.0 per cent of the Company's ordinary shares (before above-mentioned recalculation due to TO 9).

# Other information

## Review

This report has been reviewed by the Company's auditor.

## Employees

The number of employees in the Group at the end of the quarter was 47 (59). Of these, 16 (17) were men and 31 (42) were women. Of the total number of employees at the end of the quarter 38 (51) were employed within research and development.

## Future report dates

Alligator intends to publish its financial reports according to the following:

- Year-end report 2024: 13 February 2025
- Annual report 2024: March 2025
- Interim report January – March 2025: 24 April 2025

## Risks and uncertainties

During the course of its business operations, the Group is exposed to various financial risks, such as market risk (comprising foreign exchange risk, interest-rate risk and price risk), credit risk and liquidity risk. The aim of the Group's overall risk management is to achieve minimal adverse effects in terms of earnings and financial position.

The Group has transaction exposure from contracted payment flows in foreign currency. Most of the Group's transaction exposure is in USD, GBP and EUR. During 2023 a 5 % stronger/weaker SEK against the USD would have had a positive/negative effect on post-tax profits and equity of approx. +/- SEK 3,520 thousand, against the EUR of approx. +/- SEK 2,688 thousand and against the GBP of approx. +/- SEK 1,558 thousand.

The Group's business risks, risk management and financial risks are described in detail in the Annual Report for 2023.

## Conflicts in the world

Many wars and conflicts are raging around the world, resulting in enormous human suffering. The Russian invasion of Ukraine has worsened the political security situation in the rest of the world and

created great uncertainty in the financial markets, which may affect the Group's ability to finance clinical trials in the future. The conflict between Israel and Palestina has been going on for decades and has flared up many times over the years. Recently, the violence has escalated and caused enormous suffering. Some other countries around the world are also at war right now.

The Group has no direct business in, nor does it conduct any clinical studies in affected countries but sees that the Group will suffer from increased raw material and energy prices, which in turn will translate into increased prices for goods and services.

## Cyber security

Cyber-attacks have become a significant threat in society and for Alligator Bioscience, which is dependent on IT support in its daily operations. The Group has ongoing work to ensure that the Group is well prepared to counter cyber-attacks and other types of intrusion.

## Statement of financial position

The Group works continuously to secure the financing of the operation. This includes both business development for new partnering agreements, with an upfront payment upon signing, as well as other options. As the Group within the next 12 months has additional financing needs that have not yet been secured, the Board is continuously working on evaluating various financing options to ensure continued operation. It is the Board's assessment that the Group has good prospects of securing future financing, for example, through a new share issue, however, the absence of assurance at the same time of submission of this report means that there is a significant uncertainty factor regarding the Group's ability to continue operation.

## Forward-looking information

Even though the Board and management believe the expectations in this report are justified, no guarantees can be given that they will turn out to be correct. Accordingly, the actual outcome may differ significantly from the assumptions stated in the forward-looking information depending on, among other factors, changes in the economy or market, changes in legal or regulatory demands, political decisions and changes in exchange rates.

## Parent Company

Both management functions and all operating activities are carried out in the parent company. For additional details, refer to the information provided for the Group since the subsidiaries do not conduct their own operations.

## Notes to the reader

Figures in brackets refer to the outcome for the corresponding period in the preceding year for figures related to the income statement and cash flow. For figures related to the financial position and personnel, figures in brackets refer to 31 December, 2023. Unless otherwise stated, all amounts stated are rounded correctly, which may mean that some totals do not tally exactly. "Dollar" means US dollars unless otherwise stated.

## Registered trademarks

FIND®, ALLIGATOR-GOLD®, RUBY® and Neo-X-Prime® are Alligator Bioscience AB proprietary trademarks which are registered in Sweden and other countries.

## For further information, please contact:

Søren Bregenholt, CEO

Email: [soren.bregenholt@alligatorbioscience.com](mailto:soren.bregenholt@alligatorbioscience.com)

Phone: +46 46 540 82 00

Johan Giléus, CFO

Email: [johan.gileus@alligatorbioscience.com](mailto:johan.gileus@alligatorbioscience.com)

Phone: +46 46 540 82 00

Guillaume van Renterghem, LifeSci Advisors, Investor Relations

Email: [ir@alligatorbioscience.com](mailto:ir@alligatorbioscience.com)

## Alligator Bioscience AB (publ) 556597-8201

Medicon Village, Scheelevägen 2

223 81 Lund, Sweden

Phone: +46 46 540 82 00

[www.alligatorbioscience.com](http://www.alligatorbioscience.com)



# Financial statements

Unless otherwise stated in this interim report, numbers refer to the Group. Due to the nature of the business, there can be large fluctuations in revenue which are not seasonal or regular but are mainly linked to when milestones generating a payment are reached in out-licensed research projects. Like revenue, expenses can also fluctuate between periods. Among other factors, this fluctuation in expenses is influenced by the current phase of the various projects since certain phases generate higher costs. Figures in brackets refer to the outcome for the corresponding period in the preceding year for figures related to the income statement and cash flow. For figures related to the financial position and personnel, figures in brackets refer to the corresponding period in 2023. Unless stated otherwise, all amounts are in SEK thousand (KSEK). All amounts stated are rounded, which may mean that some totals do not tally exactly.

## Consolidated Income Statement

| All amounts KSEK unless specified  | Note | 2024<br>Jul-Sep | 2023<br>Jul-Sep | 2024<br>Jan-Sep | 2023<br>Jan-Sep | 2023<br>Jan-Dec |
|--|------|-----------------|-----------------|-----------------|-----------------|-----------------|
| <b>Operating income</b>  |      |                 |                 |                 |                 |                 |
| Net sales  | 5    | 1,433           | 19,414          | 15,988          | 46,369          | 58,107          |
| Other operating income   | 5    | 837             | 488             | 1,665           | 2,626           | 3,795           |
| <b>Total operating income</b>  |      | <b>2,270</b>    | <b>19,902</b>   | <b>17,653</b>   | <b>48,995</b>   | <b>61,902</b>   |
| <b>Operating costs</b>   |      |                 |                 |                 |                 |                 |
| Other external costs   |      | -46,341         | -52,471         | -123,711        | -160,394        | -218,792        |
| Personnel costs  |      | -15,715         | -16,454         | -55,153         | -57,219         | -79,377         |
| Amortization of tangible assets and intangible assets                    |      | -2,099          | -2,684          | -6,912          | -7,817          | -10,489         |
| Other operating expenses   |      | -152            | -1,014          | -930            | -2,162          | -2,227          |
| <b>Total operating costs</b>   |      | <b>-64,308</b>  | <b>-72,622</b>  | <b>-186,705</b> | <b>-227,592</b> | <b>-310,884</b> |
| <b>Operating profit/loss</b>   |      | <b>-62,038</b>  | <b>-52,720</b>  | <b>-169,052</b> | <b>-178,596</b> | <b>-248,983</b> |
| <b>Financial items</b>   |      |                 |                 |                 |                 |                 |
| Other interest income and similar income statement items                 |      | 223             | 370             | 1,142           | 447             | 1,788           |
| Interest expense and similar income statement items                      |      | -4,696          | -151            | -10,565         | -607            | -1,391          |
| <b>Net financial items</b>   |      | <b>-4,474</b>   | <b>219</b>      | <b>-9,423</b>   | <b>-160</b>     | <b>397</b>      |
| <b>Profit/loss before tax</b>  |      | <b>-66,511</b>  | <b>-52,501</b>  | <b>-178,475</b> | <b>-178,756</b> | <b>-248,586</b> |
| Tax on profit for the period   |      | -               | -               | -               | -               | -               |
| <b>Profit for the period attributable to Parent Company shareholders</b> |      | <b>-66,511</b>  | <b>-52,501</b>  | <b>-178,475</b> | <b>-178,756</b> | <b>-248,586</b> |
| <b>Earnings per share</b>  |      |                 |                 |                 |                 |                 |
| <b>Earnings per share before and after dilution, SEK</b>                 |      | <b>-0.09</b>    | <b>-0.08</b>    | <b>-0.25</b>    | <b>-0.45</b>    | <b>-0.55</b>    |

### Net Sales

Sales for the period, as well as last year period, pertain primarily to the collaboration agreement with Orion Corporation.

### Other operating income

Other operating income for the quarter comprises primarily of operational exchange gains.

### Operating costs

The Group's costs are lower compared to the same period previous year and pertain mainly to costs related to mitazalimab's OPTIMIZE-1 study that had its peak patient recruitment last year. External costs for mitazalimab amounted to SEK 29,804 thousand (33,016) during the third quarter of the year. These costs are driven by phase 3-enabling activities, e.g. production of study material and costs for the ongoing OPTIMIZE-1 study. In addition to the cost for mitazalimab activities, the ongoing dose escalation study in ALG. APV-527, has cost-wise been at the same level as the corresponding period previous year.

### Net financial items

Pertains to unrealized exchange gains and losses as a result of liquidity positions in USD, EUR and GBP and for the period this year also interest due to the newbrigde loan, the credit facility and financial costs related to the warrants (TO 9) issued in connection with the Right issue of units in April 2024.

## Consolidated Statement of Comprehensive Income

| All amounts KSEK                           | Note | 2024<br>Jul-Sep | 2023<br>Jul-Sep | 2024<br>Jan-Sep | 2023<br>Jan-Sep | 2023<br>Jan-Dec |
|--|------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Profit/loss for the period                 |      | -66,511         | -52,501         | -178,475        | -178,756        | -248,586        |
| Other comprehensive income                 |      | -               | -               | -               | -               | -               |
| <b>Comprehensive income for the period</b> |      | <b>-66,511</b>  | <b>-52,501</b>  | <b>-178,475</b> | <b>-178,756</b> | <b>-248,586</b> |

# Consolidated Statement of Financial Position

| All amounts in KSEK                    | Note | 30 Sep 2024   | 30 Sep 2023    | 31 Dec 2023    |
|--|------|---------------|----------------|----------------|
| <b>ASSETS</b>                          |      |               |                |                |
| <b>Fixed assets</b>                    |      |               |                |                |
| <b>Intangible assets</b>               |      |               |                |                |
| Participations in development projects | 3    | 17,949        | 17,949         | 17,949         |
| Softwares                              |      | -             | 21             | 15             |
| <b>Tangible assets</b>                 |      |               |                |                |
| Right of use assets                    |      | 11,657        | 19,987         | 17,613         |
| Equipment, machinery and computers     |      | 1,981         | 2,991          | 2,699          |
| <b>Financial assets</b>                |      |               |                |                |
| Other long term financial fixed assets | 6    | 2,023         | 2,057          | 1,986          |
| <b>Total fixed assets</b>              |      | <b>33,609</b> | <b>43,005</b>  | <b>40,262</b>  |
| <b>Current assets</b>                  |      |               |                |                |
| <b>Current receivables</b>             |      |               |                |                |
| Accounts receivable                    | 6    | -             | 5,660          | 2              |
| Other receivables                      | 6    | 4,712         | 5,183          | 4,521          |
| Prepayments and accrued income         |      | 5,657         | 6,333          | 7,547          |
| Other short-term financial assets      | 6    | -             | 50,000         | -              |
| Cash and cash equivalents              | 6    | 47,797        | 73,919         | 66,118         |
| <b>Total current assets</b>            |      | <b>58,166</b> | <b>141,095</b> | <b>78,188</b>  |
| <b>TOTAL ASSETS</b>                    |      | <b>91,775</b> | <b>184,100</b> | <b>118,450</b> |

## ASSETS

### Participations in development projects

The Group's participations in development projects refers to cooperation with the South Korean company AbClon Inc. for the Biosynergy project (AC101/HLX22). Biosynergy is outlicensed to the Chinese company Shanghai Henlius, which is now further developing the drug candidate. At the end of the period, participations in development projects amounted to SEK 17,949 thousand (17,949).

### Right of use assets

At the end of the period, right of use assets amounted to SEK 11,657 thousand (19,987). Right of use assets pertain to leases for offices and laboratories, machines and vehicles.

In June 2022 Alligator entered into a lease agreement with Medicon Village for office premises valid from December 2024 with an agreement period of 5 years. The new agreement is estimated to increase the right of use assets by approximately SEK 46.7 million, based on the use of the agreement period without extension, and replaces the current agreement with Medicon Village regarding office premises.

### Cash and cash equivalents

Consolidated cash and cash equivalents, which consist of bank balances, totaled SEK 47,797 thousand (73,919).

The Group plans to use its liquidity for operating activities. A portion of the Group's liquidity is invested in USD, EUR and GBP foreign currency accounts. In accordance with the Group's Financial Policy, inflows of foreign currencies exceeding the expected requirements for the coming 18 months are to be converted to SEK at the time of payment. Besides this, no further hedging has taken place.

## Consolidated Statement of Financial Position

| All amounts in KSEK                                       | Note | 30 Sep 2024    | 30 Sep 2023    | 31 Dec 2023    |
|---|------|----------------|----------------|----------------|
| <b>EQUITY AND LIABILITIES</b>                             |      |                |                |                |
| <b>Equity</b>   |      |                |                |                |
| Share capital   |      | 607            | 42,170         | 42,170         |
| Other capital contributions                               |      | 1,145,701      | 1,055,459      | 1,055,224      |
| Retained earnings and profit/loss for the period          |      | -1,222,313     | -1,015,731     | -1,085,539     |
| <b>Equity attributable to Parent Company shareholders</b> |      | <b>-76,004</b> | <b>81,897</b>  | <b>11,855</b>  |
| <b>Non-current provisions and liabilities</b>             |      |                |                |                |
| Lease liabilities   | 6    | 1,351          | 9,640          | 7,516          |
| <b>Total non-current provisions and liabilities</b>       |      | <b>1,351</b>   | <b>9,640</b>   | <b>7,516</b>   |
| <b>Current liabilities</b>                                |      |                |                |                |
| Accounts payable  | 6    | 6,846          | 11,966         | 21,273         |
| Other liabilities   | 6    | 93,511         | 1,808          | 3,261          |
| Lease liabilities   | 6    | 8,610          | 8,810          | 8,581          |
| Accrued expenses and deferred income                      | 6    | 57,461         | 69,979         | 65,964         |
| <b>Total current liabilities</b>                          |      | <b>166,428</b> | <b>92,563</b>  | <b>99,079</b>  |
| <b>TOTAL EQUITY AND LIABILITIES</b>                       |      | <b>91,776</b>  | <b>184,100</b> | <b>118,450</b> |

## Consolidated Statement of Changes in Equity, in summary

| All amounts in KSEK                      | 2024<br>Jul-Sep | 2023<br>Jul-Sep | 2024<br>Jan-Sep | 2023<br>Jan-Sep | 2023<br>Jan-Dec |
|--|-----------------|-----------------|-----------------|-----------------|-----------------|
| <b>Opening balance</b>                   | <b>-9,512</b>   | <b>121,835</b>  | <b>11,855</b>   | <b>89,051</b>   | <b>89,051</b>   |
| New capital issue                        | -               | 13,751          | 97,082          | 195,097         | 195,097         |
| Transaction costs                        | -               | -1,196          | -7,481          | -23,979         | -24,142         |
| Warrants                                 | -               | -               | 977             | 440             | 440             |
| Effect of share-based payments personnel | 21              | 8               | 59              | 52              | 74              |
| Repurchase of warrants                   | -               | -               | -19             | -9              | -82             |
| Profit/loss for the period               | -66,511         | -52,501         | -178,475        | -178,756        | -248,586        |
| <b>Closing balance</b>                   | <b>-76,004</b>  | <b>81,897</b>   | <b>-76,004</b>  | <b>81,897</b>   | <b>11,855</b>   |

### EQUITY AND LIABILITIES

#### Equity

Equity at the end of the period amounted to SEK -76,004 thousand (81,897), corresponding to an equity ratio of -83 (44) %. The total number of shares outstanding in the Company amounts to 758,989,086 of which 758,039,236 are ordinary shares and 949,850 are series C shares. The total number of votes in the Company amounts to 758,134,221.

The completed rights issue of units in April 2024, consisting of one share and a warrant to subscribe for a share in December 2024 at 90% of the volume weighted average price between November 4-29, 2024. The right to subscribe for a share at a discounted price is accounted for as a financial liability. As of 30 September 2024, valued at SEK 13,091 thousand, which means that the increase for the quarter of SEK 1,081 thousand, is reported as a financial cost in the period. Please see page 10 for additional information.

#### Equity per share before potential dilution

At the end of the period, equity per outstanding share amounted to SEK -0.10 (0.12), before dilution.

#### Lease liabilities and loans

Lease liabilities pertain to leases for offices and laboratories, machines and vehicles. At the end of the period long- and short-term lease liabilities amounted to SEK 9,961 thousand (18,450). In June 2022 Alligator entered into a lease agreement with Medicon Village for office premises valid from December 2024 with an agreement period of 5 years. The new agreement is estimated to increase the lease liabilities by approximately SEK 46.7 million, based on the use of the agreement period without extension, and replaces the current agreement with Medicon Village regarding office premises.

During the second quarter 2024, the Group entered into an agreement with Fenja Capital II A/S for a credit facility amounting to up to SEK 80,000 thousand. During the third quarter the remaining part of the credit facility was utilized, which strengthened the cash position by further SEK 30,000 thousand. According to the agreement, Fenja has the right to convert up to SEK 12,000 thousand of the borrowed amount into shares at a price of SEK 1.47 per share. The facility is accounted for as a "compound financial instrument" where a portion is recorded as a loan and another portion (the value of the right to convert parts of the loan) is accounted for as equity. The transaction costs associated with the facility have been capitalized and are amortized over the term of the loan as interest costs, however, without impacting cash flow. The value of the right to convert is handled in the same way and is accounted for as an interest cost without affecting cash flow. The short-term liabilities will increase during the term of the facility at a corresponding rate so that the liabilities amount to SEK 87,458 thousand at the end of the term. The short-term liabilities have therefore increased by SEK 79,121 thousand and the equity by SEK 474 thousand in connection with the agreement with Fenja.

#### Accrued expenses and deferred income

At the end of the period, accrued expenses and deferred income amounted to SEK 57,461 thousand (69,979). Expenses pertain to accrued expenses for clinical activities, personnel and other expenses. Accrued costs at the same level as the same period last year and are primarily related to accrued patient costs for mitazalimab's OPTIMIZE-1 study and costs related to Phase 1 study for ALG.APV-527.



# Consolidated Statement of Cash Flows

| All amounts in KSEK  | 2024<br>Jul-Sep | 2023<br>Jul-Sep | 2024<br>Jan-Sep | 2023<br>Jan-Sep | 2023<br>Jan-Dec |
|--|-----------------|-----------------|-----------------|-----------------|-----------------|
| <b>Operating activities</b>  |                 |                 |                 |                 |                 |
| Operating profit/loss  | -62,038         | -52,720         | -169,052        | -178,596        | -248,983        |
| Adjustments for items not generating cash flow                               |                 |                 |                 |                 |                 |
| Depreciation and impairments   | 2,099           | 2,684           | 6,912           | 7,817           | 10,489          |
| Effect from warrant program  | 21              | 8               | 59              | 52              | 74              |
| Other items, no impact on cash flow  | -5,519          | -               | -7,736          | -               | -2              |
| Interest received  | 340             | 473             | 1,259           | 510             | 1,883           |
| Interest paid  | -156            | -115            | -3,917          | -381            | -483            |
| <b>Cash flow from operating activities before changes in working capital</b> | <b>-65,253</b>  | <b>-49,671</b>  | <b>-172,477</b> | <b>-170,598</b> | <b>-237,021</b> |
| <b>Changes in working capital</b>  |                 |                 |                 |                 |                 |
| Change in operating receivables  | -2,797          | 572             | 1,664           | 8,090           | 13,267          |
| Change in operating liabilities  | 10,340          | 2,532           | -7,881          | 27,723          | 34,468          |
| <b>Cash flow from operating activities</b>                                   | <b>-57,710</b>  | <b>-46,567</b>  | <b>-178,694</b> | <b>-134,785</b> | <b>-189,286</b> |
| <b>Investing activities</b>  |                 |                 |                 |                 |                 |
| Acquisition of tangible assets   | -               | -39             | -               | -2,459          | -2,459          |
| <b>Cash flow from investing activities</b>                                   | <b>-</b>        | <b>-39</b>      | <b>-</b>        | <b>-2,459</b>   | <b>-2,459</b>   |
| <b>Financing activities</b>  |                 |                 |                 |                 |                 |
| Amortization of lease liabilities  | -1,832          | -2,445          | -6,136          | -7,404          | -9,754          |
| Loan   | 30,000          | -               | 80,000          | -               | -               |
| Set up fee   | -               | -               | -4,000          | -               | -               |
| New share issue  | -               | 13,751          | 97,082          | 195,097         | 195,097         |
| Transaction costs  | -               | -1,196          | -7,481          | -23,979         | -24,142         |
| Warrants   | -               | -               | 977             | 440             | 440             |
| Repurchase of warrants   | -               | -               | -19             | -9              | -82             |
| Acquisition of other short term investments                                  | -               | -50,000         | -               | -50,000         | -50,000         |
| Divestment of other short term investments                                   | -               | -               | -               | -               | 50,000          |
| <b>Cash flow from financing activities</b>                                   | <b>28,168</b>   | <b>-39,890</b>  | <b>160,424</b>  | <b>114,146</b>  | <b>161,561</b>  |
| <b>Cash flow for the period</b>  | <b>-29,543</b>  | <b>-86,495</b>  | <b>-18,270</b>  | <b>-23,098</b>  | <b>-30,184</b>  |
| <b>Cash and cash equivalents at beginning of period</b>                      | <b>77,507</b>   | <b>160,552</b>  | <b>66,118</b>   | <b>97,305</b>   | <b>97,305</b>   |
| Exchange rate differences in cash and cash equivalents                       | -168            | -137            | -51             | -288            | -1,004          |
| <b>Cash and cash equivalents at end of period</b>                            | <b>47,797</b>   | <b>73,919</b>   | <b>47,797</b>   | <b>73,919</b>   | <b>66,118</b>   |

## Investments

No investments were made under the third quarter of 2024 (SEK 39 thousand). Investments during the year amount to SEK 0 thousand (2,459).

## Cash flow for the period

Cash flow for the third quarter totaled SEK -29,543 thousand (-86,495). The credit facility has had a positive effect of SEK 30,000 thousand on the cash flow during the period.

## Parent Company Income Statement

| All amounts in KSEK  | Note | 2024<br>Jul-Sep | 2023<br>Jul-Sep | 2024<br>Jan-Sep | 2023<br>Jan-Sep | 2023<br>Jan-Dec |
|--|------|-----------------|-----------------|-----------------|-----------------|-----------------|
| <b>Operating income</b>  |      |                 |                 |                 |                 |                 |
| Net sales  | 5    | 1,433           | 19,414          | 15,988          | 46,369          | 58,107          |
| Other operating income   | 5    | 837             | 488             | 1,665           | 2,626           | 3,795           |
| <b>Total operating income</b>  |      | <b>2,270</b>    | <b>19,902</b>   | <b>17,653</b>   | <b>48,995</b>   | <b>61,902</b>   |
| <b>Operating costs</b>   |      |                 |                 |                 |                 |                 |
| Other external costs   |      | -48,641         | -54,977         | -130,365        | -167,695        | -228,487        |
| Personnel costs  |      | -15,715         | -16,454         | -55,153         | -57,219         | -79,377         |
| Depreciation and impairment of tangible assets and intangible assets |      | -236            | -309            | -734            | -903            | -1,200          |
| Other operating expenses   |      | -152            | -1,014          | -930            | -2,162          | -2,227          |
| <b>Total operating costs</b>   |      | <b>-64,744</b>  | <b>-72,754</b>  | <b>-187,181</b> | <b>-227,979</b> | <b>-311,291</b> |
| <b>Operating profit/loss</b>   |      | <b>-62,474</b>  | <b>-52,851</b>  | <b>-169,528</b> | <b>-178,983</b> | <b>-249,389</b> |
| <b>Results from financial items</b>                                  |      |                 |                 |                 |                 |                 |
| Other interest income and similar income statement items             |      | 223             | 370             | 1,142           | 447             | 1,788           |
| Interest expense and similar income statement items                  |      | -3,547          | -36             | -7,252          | -226            | -910            |
| <b>Net financial items</b>   |      | <b>-3,324</b>   | <b>334</b>      | <b>-6,110</b>   | <b>221</b>      | <b>878</b>      |
| <b>Profit/loss after financial items</b>                             |      | <b>-65,798</b>  | <b>-52,517</b>  | <b>-175,638</b> | <b>-178,762</b> | <b>-248,511</b> |
| <b>Appropriations</b>  |      |                 |                 |                 |                 |                 |
| Group contribution received  |      | -               | -               | -               | -               | 354             |
| <b>Total appropriations</b>  |      | <b>-</b>        | <b>-</b>        | <b>-</b>        | <b>-</b>        | <b>354</b>      |
| <b>Result before tax</b>   |      | <b>-65,798</b>  | <b>-52,517</b>  | <b>-175,638</b> | <b>-178,762</b> | <b>-248,158</b> |
| Tax on profit for the year   |      | -               | -               | -               | -               | -               |
| <b>Profit/loss for the period</b>                                    |      | <b>-65,798</b>  | <b>-52,517</b>  | <b>-175,638</b> | <b>-178,762</b> | <b>-248,158</b> |

## Parent Company Statement of Comprehensive Income

| All amounts in KSEK             | Note | 2024<br>Jul-Sep | 2023<br>Jul-Sep | 2024<br>Jan-Sep | 2023<br>Jan-Sep | 2023<br>Jan-Dec |
|---------------------------------|------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Profit/loss for the period      |      | -65,798         | -52,517         | -175,638        | -178,762        | -248,158        |
| Other comprehensive income      |      | -               | -               | -               | -               | -               |
| <b>Profit/loss for the year</b> |      | <b>-65,798</b>  | <b>-52,517</b>  | <b>-175,638</b> | <b>-178,762</b> | <b>-248,158</b> |

# Parent Company

## Balance Sheet

| All amounts in KSEK                    | Note | 2024-09-30    | 2023-09-30     | 2023-12-31     |
|--|------|---------------|----------------|----------------|
| <b>ASSETS</b>                          |      |               |                |                |
| <b>Fixed assets</b>                    |      |               |                |                |
| <b>Intangible assets</b>               |      |               |                |                |
| Software                               |      | -             | 21             | 15             |
| <b>Total intangible assets</b>         |      | <b>-</b>      | <b>21</b>      | <b>15</b>      |
| <b>Tangible assets</b>                 |      |               |                |                |
| Equipment, machinery and computers     |      | 1,981         | 2,991          | 2,699          |
| <b>Total tangible assets</b>           |      | <b>1,981</b>  | <b>2,991</b>   | <b>2,699</b>   |
| <b>Financial assets</b>                |      |               |                |                |
| Participations in Group companies      | 3    | 20,294        | 20,294         | 20,294         |
| Other long term financial fixed assets |      | 2,023         | 2,057          | 1,986          |
| <b>Total financial assets</b>          |      | <b>22,317</b> | <b>22,351</b>  | <b>22,280</b>  |
| <b>Total fixed assets</b>              |      | <b>24,298</b> | <b>25,363</b>  | <b>24,995</b>  |
| <b>Current assets</b>                  |      |               |                |                |
| <b>Current receivables</b>             |      |               |                |                |
| Accounts receivables                   |      | -             | 5,660          | 2              |
| Receivables from Group companies       |      | 1,199         | 845            | 1,199          |
| Other receivables                      |      | 4,710         | 5,183          | 4,520          |
| Prepayments and accrued income         |      | 7,835         | 8,746          | 9,961          |
| <b>Total current receivables</b>       |      | <b>13,744</b> | <b>20,434</b>  | <b>15,681</b>  |
| Other short-term investments           |      | -             | 50,000         | -              |
| Cash and bank deposits                 |      | 45,708        | 72,233         | 64,510         |
| <b>Total current assets</b>            |      | <b>59,452</b> | <b>142,667</b> | <b>80,191</b>  |
| <b>TOTAL ASSETS</b>                    |      | <b>83,750</b> | <b>168,029</b> | <b>105,186</b> |

# Parent Company

## Balance Sheet

| All amounts in KSEK                  | Note | 2024-09-30     | 2023-09-30     | 2023-12-31     |
|--------------------------------------|------|----------------|----------------|----------------|
| <b>EQUITY AND LIABILITIES</b>        |      |                |                |                |
| <b>Equity</b>                        |      |                |                |                |
| <b>Restricted equity</b>             |      |                |                |                |
| Share capital                        |      | 607            | 42,170         | 42,170         |
| <b>Total restricted equity</b>       |      | <b>607</b>     | <b>42,170</b>  | <b>42,170</b>  |
| <b>Non-restricted equity</b>         |      |                |                |                |
| Share premium reserve                |      | 1,144,445      | 1,054,614      | 1,054,452      |
| Retained earnings                    |      | -1,040,678     | -834,245       | -834,223       |
| Profit/loss for the period           |      | -175,638       | -178,762       | -248,158       |
| <b>Total non-restricted equity</b>   |      | <b>-71,872</b> | <b>41,607</b>  | <b>-27,928</b> |
| <b>Total equity</b>                  |      | <b>-71,265</b> | <b>83,777</b>  | <b>14,241</b>  |
| <b>Current liabilities</b>           |      |                |                |                |
| Accounts payable                     |      | 6,840          | 11,966         | 21,273         |
| Other liabilities                    |      | 90,429         | 1,808          | 3,262          |
| Accrued expenses and deferred income |      | 57,747         | 70,478         | 66,410         |
| <b>Total current liabilities</b>     |      | <b>155,015</b> | <b>84,252</b>  | <b>90,944</b>  |
| <b>TOTAL EQUITY AND LIABILITIES</b>  |      | <b>83,750</b>  | <b>168,029</b> | <b>105,186</b> |

### EQUITY AND LIABILITIES

#### Equity

The Board has noted that the equity is below half of the registered share capital. The Board has considered the provisions in Chap. 25 in the Swedish Companies Act and concluded that the Company has significant surplus values (in amongst others, the mitazalimab project) that with good margin restores the share capital.



# Notes

## Note 1 General information

This Interim report covers the Swedish Parent company Alligator Bioscience AB (publ), corporate registration number 556597-8201, and its subsidiaries Atlas Therapeutics AB, corporate registration number 556815-2424, and A Bioscience Incentive AB, corporate registration number 559056-3663. Group's business operations are mainly carried out in the Parent company.

The Parent company is a Swedish public limited liability company registered and domiciled in the Municipality of Lund. The office is located at Medicon Village, SE-223 81 Lund.

## Note 2 Accounting policies

This Interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and applicable regulations in the Swedish Annual Accounts Act (ÅRL). The interim report for the Parent company has been prepared in accordance with the Swedish Annual Accounts Act (ÅRL) and the Swedish Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities.

The accounting policies and calculation methods used in this report are the same as those described in the Annual report for 2023.

## Note 3 Effects of changed estimates and judgments

Significant estimates and judgments are described in Note 3 and Note 18 of the Annual report for 2023. There have been no changes to the Group's estimates and judgments since the Annual report for 2023 was prepared.

## Note 4 Segment reporting

The Group conducts only one business activity, namely research and development in the field of immunotherapy, and the chief operating decision-maker is thus only responsible for regularly making decisions on and allocating resources to one entity. Accordingly, the Group comprises only one operating segment, which corresponds to the Group as a whole, and no separate segment reporting is consequently not provided.

## Note 5 Consolidated Income

A breakdown of the Group's revenue regarding license revenue as follows:

| All amounts in KSEK                | 2024<br>Jul-Sep | 2023<br>Jul-Sep | 2024<br>Jan-Sep | 2023<br>Jan-Sep | 2023<br>Jan-Dec |
|------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Licensing income                   | -               | 5,906           | 5,820           | 11,500          | 11,500          |
| Reimbursement for development work | 1,441           | 13,508          | 10,168          | 34,869          | 46,607          |
| Other                              | -7              | -               | -               | -               | -               |
| <b>Total</b>                       | <b>1,434</b>    | <b>19,414</b>   | <b>15,988</b>   | <b>46,369</b>   | <b>58,107</b>   |

A breakdown of the Group's other operating income is as follows:

| All amounts in KSEK                | 2024<br>Jul-Sep | 2023<br>Jul-Sep | 2024<br>Jan-Sep | 2023<br>Jan-Sep | 2023<br>Jan-Dec |
|------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Swedish government grants received | 63              | 262             | -107            | 989             | 1,144           |
| Operational exchange rate gains    | 774             | 227             | 1,732           | 1,620           | 2,632           |
| Other                              | -               | -               | 40              | 18              | 18              |
| <b>Total</b>                       | <b>837</b>      | <b>488</b>      | <b>1,665</b>    | <b>2,626</b>    | <b>3,795</b>    |

### Note 6 Financial instruments

Cash and cash equivalents for the Group at 30 September 2024 consisted of bank balances amounting to SEK 47,797 thousand (73,919). For financial assets and liabilities, the reported value as below is considered a reasonable approximation of fair value.

| All amounts in KSEK                                   | 2024-09-30     | 2023-09-30     | 2023-12-31    |
|---|----------------|----------------|---------------|
| <b>Financial assets valued at amortized cost</b>      |                |                |               |
| Other long term financial fixed assets                | 2,023          | 2,057          | 1,986         |
| Other short term investments                          | -              | 50,000         | -             |
| Accounts receivable                                   | -              | 5,660          | 2             |
| Other receivables                                     | 6              | 6              | 24            |
| Liquid assets - bank accounts                         | 47,797         | 73,919         | 66,118        |
| <b>Total financial assets</b>                         | <b>49,825</b>  | <b>131,642</b> | <b>68,130</b> |
| <b>Financial liabilities valued at amortized cost</b> |                |                |               |
| Long-term lease liabilities                           | 1,351          | 9,640          | 7,516         |
| Accounts payable                                      | 6,846          | 11,966         | 21,273        |
| Short-term lease liabilities                          | 8,610          | 8,810          | 8,581         |
| Other short-term liabilities                          | 88,682         | -              | -             |
| Accrued expenses                                      | 51,805         | 64,887         | 61,474        |
| <b>Total financial liabilities</b>                    | <b>157,294</b> | <b>95,302</b>  | <b>98,844</b> |

### Note 7 Related party transactions

In order to secure the Group's liquidity needs until the Rights issue 2024 was completed, the Group raised in February 2024 bridge loans of approximately SEK 58.8 millions from Koncentra and Roxette Photo SA. A compensation for the loans, an arrangement fee of 5 per cent and an annual interest rate of 8 per cent from disbursement of the loans have been paid. The subscription undertakings that Koncentra and Roxette Photo SA provided were fulfilled by offsetting the loans and accrued interests in the Rights issue in April 2024.

In connection with the Rights issue 2023, Alligator entered in March 2023 into an agreement on a top guarantee of MSEK 10 with Alligator's largest shareholder Koncentra, in which board member Staffan Enkrantz is chairman of the board of directors. Furthermore, Alligator entered in March 2023 into an agreement of a top guarantee of MSEK 0.5 and a bottom guarantee of MSEK 0.5 with board member Hans-Peter Ostler. For the guarantee commitments, cash compensation of 11 per cent of the guaranteed amounts was paid for the bottom guarantee, and of 14 per cent of the guaranteed amount for the top guarantees. The guarantee compensation was paid in June 2023 after the Swedish Companies Registration Office registered the Rights issue.

In addition to the above, the Group has not carried out any other related party transactions during 2024 or during the previous year. All transactions with related parties have been carried out at arm's length.

# Financial definitions

## **Equity per share after dilution**

Equity divided by the total number of shares at the end of the period and any outstanding options where the Company's share price on the reporting date is at least equal to the conversion price of the option.

## **Equity per share before dilution**

Equity divided by the number of shares at the end of the period.

## **R&D costs**

The Company's direct costs for research and development. Refers to costs for personnel, materials and external services.

## **R&D costs as a percentage of operating costs excluding impairments**

R&D costs as a percentage of operating costs excluding impairments.

## **Average number of shares before and after dilution**

Average number of outstanding shares during the period. The number of shares after dilution also takes account of outstanding options where the Company's share price on the reporting date is at least equal to the conversion price of the option.

## **Average number of employees**

Average number of employees at the beginning and end of the period.

## **Average number of employees within R&D**

Average number of employees within the Company's R&D departments at the beginning and end of the period.

## **Cash flow from operating activities**

Cash flow before investing and financing activities.

## **Cash and cash equivalents, including securities**

Cash and cash equivalents consists of bank balances, interest funds and publicly traded corporate bonds.

## **Cash flow for the period**

Net change in cash and cash equivalents excluding the impact of unrealized foreign exchange gains and losses.

## **Earnings per share before and after dilution**

Earnings divided by the weighted average number of shares during the period before and after dilution respectively. If the result is negative, the number of shares before dilution is also used for the calculation after dilution.

## **Operating costs excluding impairments**

Other external costs, personnel costs and depreciation (excluding impairments of tangible and intangible assets).

## **Operating profit/loss**

Profit/loss before financial items and taxes.

## **Equity ratio**

Equity as a percentage of total assets.

## **Total assets**

Total of the Company's assets.

# Alternative Performance Measures

| All amounts KSEK unless specified                              | 2024<br>Jul-Sep | 2023<br>Jul-Sep | 2024<br>Jan-Sep | 2023<br>Jan-Sep | 2023<br>Jan-Dec |
|--|-----------------|-----------------|-----------------|-----------------|-----------------|
| Profit/loss for the period                                     | -66,511         | -52,501         | -178,475        | -178,756        | -248,586        |
| Average number of shares before dilution                       | 758,039,236     | 632,567,111     | 725,481,482     | 399,466,214     | 448,489,815     |
| <b>Earnings per share before dilution, SEK</b>                 | <b>-0.09</b>    | <b>-0.08</b>    | <b>-0.25</b>    | <b>-0.45</b>    | <b>-0.55</b>    |
| Average number of shares after dilution                        | 758,039,236     | 632,567,111     | 725,481,482     | 399,466,214     | 448,489,815     |
| <b>Earnings per share after dilution, SEK</b>                  | <b>-0.09</b>    | <b>-0.08</b>    | <b>-0.25</b>    | <b>-0.45</b>    | <b>-0.55</b>    |
| Operating costs  | -64,308         | -72,622         | -186,705        | -227,592        | -310,884        |
| <b>Operating costs excluding impairments</b>                   | <b>-64,308</b>  | <b>-72,622</b>  | <b>-186,705</b> | <b>-227,592</b> | <b>-310,884</b> |
| Reduce of administrative expenses                              | 9,538           | 6,987           | 28,766          | 26,297          | 35,809          |
| Reduce of depreciation   | 2,099           | 2,684           | 6,912           | 7,817           | 10,489          |
| <b>Research and development costs</b>                          | <b>-52,671</b>  | <b>-62,952</b>  | <b>-151,027</b> | <b>-193,477</b> | <b>-264,585</b> |
| <b>R&amp;D costs / Operating costs excluding impairments %</b> | <b>82%</b>      | <b>87%</b>      | <b>81%</b>      | <b>85%</b>      | <b>85%</b>      |
| Equity   | -76,004         | 81,897          | -76,004         | 81,897          | 11,855          |
| Average number of shares before dilution                       | 758,039,236     | 657,954,290     | 758,039,236     | 657,954,290     | 657,954,290     |
| <b>Equity per share before dilution, SEK</b>                   | <b>-0.10</b>    | <b>0.12</b>     | <b>-0.10</b>    | <b>0.12</b>     | <b>0.02</b>     |
| Average number of shares after dilution                        | 758,039,236     | 657,954,290     | 758,039,236     | 657,954,290     | 657,954,290     |
| <b>Equity per share after dilution, SEK</b>                    | <b>-0.10</b>    | <b>0.12</b>     | <b>-0.10</b>    | <b>0.12</b>     | <b>0.02</b>     |
| Equity   | -76,004         | 81,897          | -76,004         | 81,897          | 11,855          |
| Total assets   | 91,775          | 184,100         | 91,775          | 184,100         | 118,450         |
| <b>Equity ratio, %</b>   | <b>-83%</b>     | <b>44%</b>      | <b>-83%</b>     | <b>44%</b>      | <b>10%</b>      |
| Other short-term financial assets (interest funds)             | -               | 50,000          | -               | 50,000          | -               |
| Cash and cash equivalents                                      | 47,797          | 73,919          | 47,797          | 73,919          | 66,118          |
| <b>Cash and cash equivalents at end of period</b>              | <b>47,797</b>   | <b>123,919</b>  | <b>47,797</b>   | <b>123,919</b>  | <b>66,118</b>   |

For definitions, see the section "Financial definitions" on page 23.

Alligator presents certain financial performance measures in this report, including measures that are not defined under IFRS. The Group believes that these performance measures are an important complement because they allow for a better evaluation of the Group's financial trends. These financial performance measures should not be viewed in isolation or be considered to replace the performance indicators that have been prepared in accordance with IFRS. In addition, such performance measures as Alligator has defined them should not be compared with other performance measures with similar names used by other companies. This is because the above-mentioned performance measures are not always defined in the same manner, and other companies may calculate them differently to Alligator.

To the right is shown the calculation of key figures, for the mandatory earnings per share according to IFRS and also for performance measures that are not defined under IFRS or where the calculation is not shown in another table in this report.

The Group's business operation is to conduct research and development which is why "R&D costs/Operating costs excluding impairment in percent" is an essential indicator as a measure of efficiency, and how much of the Group's costs relate to R&D.

The Group does not have a steady flow of income, with income generated irregularly in connection with the signing of license agreements and achievement of milestones. Therefore, the Group monitors performance indicators such as equity ratio and equity per share in order to assess the Group's solvency and financial stability. These are monitored along with the cash position and the various measures of cash flows shown in the consolidated statement of cash flow.

# The declaration of the Board of Directors and the CEO



*Anders Ekblom*



*Hans-Peter Ostler*



*Eva Sjökvist Saers*



*Staffan Encrantz*



*Denise Goode*



*Karin Nordbladh*



*Søren Bregenholt*

The Board and the CEO declare that this Interim report provides a true and fair overview of the Company and the Group's operations, positions and earnings and describes the material risks and uncertainty factors faced by the Parent company and the companies within the Group.

Lund, October 24, 2024

**Anders Ekblom**  
Chairman of the Board

**Hans-Peter Ostler**  
Vice chairman of the Board

**Eva Sjökvist Saers**  
Board member

**Staffan Encrantz**  
Board member

**Denise Goode**  
Board member

**Karin Nordbladh**  
Board member  
*Employee representative*

**Søren Bregenholt**  
CEO

# Review report

**Alligator Bioscience AB (publ), corporate identity number 556597-8201**

**To the Board of Directors of Alligator Bioscience AB (publ)**

## Introduction

We have reviewed the condensed interim report for Alligator Bioscience AB (publ) as at September 30, 2024 and for the nine months period then ended. The Board of Directors and the Managing Director are responsible for the preparation and presentation of this interim report in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

## Scope of review

We conducted our review in accordance with the International Standard on Review Engagements, ISRE 2410 Review of Interim Financial Statements Performed by the Independent Auditor of the Entity. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and other generally accepted auditing standards in Sweden. The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

## Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material aspects, in accordance with IAS 34 and the Swedish Annual Accounts Act regarding the Group, and in accordance with the Swedish Annual Accounts Act regarding the Parent Company.

## Significant Uncertainty Related to the entity's ability to continue as Going Concern

We would like to draw attention to the section "Statement of financial position" on page 12 in the interim report where it is described that there is ongoing work related to the continued financing of the operations. The ongoing work means that the company does not, at the time of issuing our review report, have secured funding. This condition indicates that there is a material uncertainty that may cast significant doubt on the company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Malmö, October 24, 2024

Öhrlings PricewaterhouseCoopers AB

**Ola Bjärehäll**

Authorized Public Accountant



